Regenxbio Positive Data for RGX-314
Regenxbio (RGNX) reported positive one-year data from patients in Cohorts 4 and 5 from Phase I/IIa trial of RGX-314 for wet age-related macular degeneration (wet AMD).
Regenxbio plans to initiate a pivotal program for the subretinal delivery of the gene therapy RGX-314 in patients . . .
This content is for paid subscribers.
Today’s Highlights
August 4, 2020
